Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07263230 · ClinicalTrials.gov registry record · Phase 2
The Safety and Efficacy of Roflumilast Foam in HS
A Phase 2 study of Hidradenitis Suppurativa (HS), sponsored by Beth Israel Deaconess Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07263230 is a Phase 2 study of Hidradenitis Suppurativa (HS) that is actively recruiting participants, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 20 participants, below the 179-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07263230, a Phase 2 study of Hidradenitis Suppurativa (HS), is actively recruiting participants, sponsored by Beth Israel Deaconess Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study investigates the efficacy of topical roflumilast foam in patients with HS.
Conditions Studied
Interventions
- DRUG Roflumilast 0.3% topical foam
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07263230
The ClinicalTrials.gov registry entry for NCT07263230 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (89% lower). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hidradenitis Suppurativa (HS) appearing as the primary indexed condition, and to 1 intervention - of which Roflumilast 0.3% topical foam is the first listed.
NCT07263230 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07263230 about?
NCT07263230 is a clinical study titled "The Safety and Efficacy of Roflumilast Foam in HS". This study investigates the efficacy of topical roflumilast foam in patients with HS.
What is the current status of trial NCT07263230?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2026-04-01. Estimated completion is 2028-12.
What conditions does trial NCT07263230 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa (HS).
What interventions are being tested in trial NCT07263230?
The interventions under investigation include: Roflumilast 0.3% topical foam (DRUG).
Who is sponsoring clinical trial NCT07263230?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07263230 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa (HS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
RECRUITING · Phase 2
-
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
Hidradenitis Suppurativa Wound Care
COMPLETED · Phase 2
-
Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.